Citadel Advisors’s KORU Medical Systems KRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-11,800
Closed -$45.4K 15082
2024
Q4
$45.4K Buy
11,800
+8,000
+211% +$26K ﹤0.01% 12486
2024
Q3
$10.4K Buy
3,800
+3,500
+1,167% +$8.63K ﹤0.01% 13208
2024
Q2
$795 Buy
+300
New +$686 ﹤0.01% 13912
2024
Q1
Sell
-1,300
Closed -$3.19K 15066
2023
Q4
$3.19K Sell
1,300
-1,200
-48% -$2.86K ﹤0.01% 13620
2023
Q3
$6.75K Buy
2,500
+1,100
+79% +$3.01K ﹤0.01% 13302
2023
Q2
$4.83K Sell
1,400
-200
-13% -$785 ﹤0.01% 13566
2023
Q1
$6.75K Buy
1,600
+1,500
+1,500% +$5.9K ﹤0.01% 13779
2022
Q4
$357 Buy
+100
New +$276 ﹤0.01% 14685
2021
Q3
Sell
-27,300
Closed -$126K 14268
2021
Q2
$126K Sell
27,300
-12,700
-32% -$49.9K ﹤0.01% 12693
2021
Q1
$141K Buy
40,000
+14,900
+59% +$64.5K ﹤0.01% 12122
2020
Q4
$151K Buy
25,100
+13,800
+122% +$77.2K ﹤0.01% 9937
2020
Q3
$82K Buy
+11,300
New +$100K ﹤0.01% 9380

Other funds holding KRMD

Citadel Advisors's KRMD Position: Q1 2026 in Review

Citadel Advisors increased its KORU Medical Systems (KRMD) stake by 27% in Q1 2026, buying an estimated $51.6K and bringing the position to 48,726 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #11316.

Citadel Advisors first reported a position in KRMD in Q3 2020 and has held it in 19 quarters since. The position peaked at $464K in Q4 2020. 91 funds tracked by Wall St. Rank hold KRMD as of Q1 2026.

  • Citadel Advisors held 48,726 shares of KORU Medical Systems worth $210K as of Q1 2026.
  • Citadel Advisors bought 10,413 KORU Medical Systems shares in Q1 2026, an estimated $51.6K.
  • KORU Medical Systems made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11316 holding.
  • Citadel Advisors first reported a position in KORU Medical Systems in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's KORU Medical Systems position peaked at $464K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held KORU Medical Systems as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.